Stories
Lupin Launches World First Triple Combination COPD Inhaler in India
M
Moneycontrol•06-10-2026, 13:15
Lupin Launches World First Triple Combination COPD Inhaler in India
- •Drug maker Lupin Ltd launched Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler for COPD management in India.
- •The launch follows approval from the Drug Controller General of India.
- •The inhaler combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate into a single twice-daily product.
- •The therapy targets over 55 million people suffering from COPD in India, which is a leading cause of death and disability.
- •Lupin is currently ranked second in the respiratory therapy segment in India based on market data.
Key Questions Answered
Lupin launched Formoflo-G MDI, a fixed-dose triple combination metered-dose inhaler for the management of chronic obstructive pulmonary disease in India.
The launch of the new COPD inhaler follows approval from the Drug Controller General of India.
Formoflo-G MDI combines Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate into a single inhaler for treating moderate to severe COPD.
